(Q45855065)

17 December 2017

title

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience (English)

1 reference

17 December 2017

1 reference

7

V S Blanchette

1 reference

17 December 2017

author name string

M Carcao

1

1 reference

17 December 2017

J St Louis

2

1 reference

17 December 2017

M-C Poon

3

1 reference

17 December 2017

E Grunebaum

4

1 reference

17 December 2017

S Lacroix

5

1 reference

17 December 2017

A M Stain

6

1 reference

17 December 2017

G E Rivard

8

1 reference

17 December 2017

Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada

9

1 reference

17 December 2017

publication date

1 January 2006

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

12

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

7-18

1 reference

17 December 2017

Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Factor VIII inhibitors in mild and moderate-severity haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Immune tolerance: a synopsis of the international experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Rituximab: clinical development and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Clinical applications of anti-CD20 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Comparative pharmacokinetic studies in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01170.X

10.1111/J.1365-2516.2005.01170.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017